Cargando…

Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent

Detalles Bibliográficos
Autores principales:	Niscola, Pasquale, Tendas, Andrea, Scaramucci, Laura, Giovannini, Marco, Fratoni, Stefano, de Fabritiis, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486154/ https://www.ncbi.nlm.nih.gov/pubmed/26157782 http://dx.doi.org/10.5045/br.2015.50.2.113

Ejemplares similares

Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome
por: Niscola, Pasquale, et al.
Publicado: (2013)

Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
por: Tendas, Andrea, et al.
Publicado: (2014)

Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia
por: Niscola, Pasquale, et al.
Publicado: (2015)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Late but effective long-term response to splenectomy in the treatment of immune thrombocytopenia
por: Scaramucci, Laura, et al.
Publicado: (2013)

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy
por: Niscola, Pasquale, et al.
Publicado: (2014)

Long-term survival of a patient with bone marrow gelatinous degeneration of idiopathic origin
por: Niscola, Pasquale, et al.
Publicado: (2012)

Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy
por: Niscola, Pasquale, et al.
Publicado: (2014)

Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency
por: Scaramucci, Laura, et al.
Publicado: (2016)

PB2033: ADVANCED CHRONIC MYELOMONOCYTIC LEUKEMIA IN ELDERLY AND FRAIL PATIENTS MANAGED BY AZACITIDINE IN THE FIELD OF CLINICAL PRACTICE.
por: Niscola, Pasquale, et al.
Publicado: (2023)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis
por: Niscola, Pasquale, et al.
Publicado: (2013)

Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
por: Niscola, Pasquale, et al.
Publicado: (2013)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Fever of unknown origin, anemia and thrombocytosis as early symptoms and signs of a late-onset polymialgia rheumatica: A diagnostic challenge
por: Niscola, Pasquale, et al.
Publicado: (2012)

Idiopathic thrombocytopenic purpura coexisting with polycythemia vera
por: Niscola, Pasquale, et al.
Publicado: (2011)

IgA-induced autoimmune hemolytic anemia in a patient with antiphospholipid syndrome
por: Scaramucci, Laura, et al.
Publicado: (2012)

Managing myelodysplastic syndromes in very old patients: a teaching case report
por: Niscola, Pasquale, et al.
Publicado: (2013)

Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab
por: Tendas, Andrea, et al.
Publicado: (2016)

Pain in Blood Cancers
por: Niscola, Pasquale, et al.
Publicado: (2011)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
por: Garcia-Manero, G, et al.
Publicado: (2017)

Primary mixed-type autoimmune hemolytic anemia concomitant with acute splanchnic venous thrombosis of idiopathic origin in a young woman: an unexplained association
por: Scaramucci, Laura, et al.
Publicado: (2013)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
por: Hirano, Mitsuhito, et al.
Publicado: (2022)

Primary diffuse large B-cell lymphoma of the bone marrow in a frail and elderly patient successfully treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
por: Niscola, Pasquale, et al.
Publicado: (2013)

Authors’ Reply
por: Tendas, Andrea, et al.
Publicado: (2011)

Anticoagulant and Anti-thrombotic Treatments in the Management of Hematological Malignancies in a Home Care Program
por: Tendas, Andrea, et al.
Publicado: (2011)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?
por: Palombi, Massimiliano, et al.
Publicado: (2016)

MDS subclassification—do we still have to count blasts?
por: Huber, Sandra, et al.
Publicado: (2023)

IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
por: Leisch, Michael, et al.
Publicado: (2020)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts
por: Coyle, D., et al.
Publicado: (2019)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

P689: CLASSIFICATION OF MDS AND AML BASED SOLELY ON GENETICS OMITTING BLAST COUNTING – A WAY TO RESOLVE THE DISCREPANCIES BETWEEN CLASSIFICATIONS ACCORDING TO WHO AND ICC?
por: Haferlach, Claudia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_67ndeatu3lp5sv8tu84bcc159e